CD274 and non-small cell lung carcinoma: But in the OAK study of non-small cell lung cancer (NSCLC) patients treated with atezolizumab, patients with low or negative PD-L1 (PD-L1 expression < 1%) also had a longer median OS than those treated with docetaxel (12.6 months vs 8.9 months), while clinical benefit was more significant in patients with positive PD-L1 expression 8.